Details of the Drug Reposition

General Information of This Drug (ID: DM3AVO1)

Drug Name
DE-081   DM3AVO1
Synonyms
Apafant; 105219-56-5; WEB-2086; Web 2086; Apafant [USAN:INN]; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; WEB 2086BS; WEB2086; UNII-J613NI05SV; WEB 2086 BS; BRN 4302553; C22H22ClN5O2S; J613NI05SV; CHEMBL280164; NCGC00092377-03; NCGC00092377-02; Apafantum; Apafanto; DSSTox_CID_28900; DSSTox_RID_83168; DSSTox_GSID_48974; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; [3H]apafant; Morpholine; Apafant (ophthalmic formulation), Santen
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Conjunctivitis DISGOZ4P 9A60 Discontinued in Phase 2 [1]
------------------------------------------------------------------------------------
1 Terminated Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ocular allergy DIS38BN3 4A81 Terminated [2]
------------------------------------------------------------------------------------

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000113)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1860).